| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-2182 | |
| Phytochemical name or plant extracts | Carpesium cernuum extract | |
| PMID | 31480012 | |
| Literature evidence | Transcriptome analysis showed that CCE significantly affected the cell adhesion pathway. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Ethanolic extract | |
| Source of phytochemicals or plant Extracts | Carpesium cernuum | |
| Geographical availability | Afghanistan, Assam, Austria, Borneo, Bulgaria, China North-Central, China South-Central, China Southeast, Corse, Czechoslovakia, France, Hungary, Iran, Italy, Japan, Korea, Manchuria, Nansei-shoto, North Caucasus, Pakistan, Philippines, Primorye, Romania, Spain, Switzerland, Taiwan, Tibet, Transcaucasus, Turkey, Ukraine, West Himalaya, Yugoslavia | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Lung cancer | |
| Target gene or protein | MMP9, CD44, COL4A2, TIMP1 | |
| Gene or Protein evidence | . In summary, CCE downregulated the clinically high-risk metastasis promoting genes MMP9, CD44 and COL4A2, while upregulated the MMP9 inhibitor TIMP1, indicating an anti-metastasis potential. | |
| Target pathways | Cell adhesion pathway | |
| IC50 | 3.0 μg/ml against MDA-MB-231 6.5 μg/ml against MCF-7 | |
| Potency | Overall, both molecular and phenotypic assays showed that CCE has potential in the treatment of breast cancer, especially for the treatment of breast cancer metastasis. CCE-derived sesquiterpene lactone substances are the foundation for the tumor inhibitory effect of CCE. | |
| Cell line/ mice model | MDA-MB-231, MCF-7, A549 | |
| Additional information | ranscriptome analysis showed that CCE significantly affected the cell adhesion pathway. Further experiments revealed that CCE suppressed cell migration and invasion. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:189333-1 | |
| Safety | NA |